Lawrence Banks

Q: What Schools Are Affiliated With Lawrence Banks

Lawrence Banks is affiliated with the following schools: University of Trieste, Stanford University

Lawrence Banks's AcademicInfluence.com Rankings

Lawrence Banks

Computer Science

#7067

World Rank

#7444

Historical Rank

Artificial Intelligence

#2781

World Rank

#2825

Historical Rank

Database

#4127

World Rank

#4293

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Lawrence Banks's Degrees

PhD Computer Science Stanford University

Similar Degrees You Can Earn

Best Online PhD of Computer Science (Doctorates) 2026

Why Is Lawrence Banks Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence Banks's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The biology and life-cycle of human papillomaviruses. (2012) (1122)
Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer (1998) (1042)
Two Polymorphic Variants of Wild-Type p53 Differ Biochemically and Biologically (1999) (752)
The Human Papillomavirus E6 protein and its contribution to malignant progression (2001) (521)
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. (1986) (503)
The role of the E6-p53 interaction in the molecular pathogenesis of HPV (1999) (430)
p53 polymorphic variants at codon 72 exert different effects on cell cycle progression (2004) (412)
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. (1987) (336)
Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation (1999) (320)
Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. (2000) (320)
Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins (2000) (311)
Inhibition of Bak-induced apoptosis by HPV-18 E6 (1998) (307)
Comparison of the in vitro transforming activities of human papillomavirus types. (1988) (289)
Multi-PDZ Domain Protein MUPP1 Is a Cellular Target for both Adenovirus E4-ORF1 and High-Risk Papillomavirus Type 18 E6 Oncoproteins (2000) (275)
Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. (1999) (264)
Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. (1992) (251)
Continued expression of HPV‐16 E7 protein is required for maintenance of the transformed phenotype of cells co‐transformed by HPV‐16 plus EJ‐ras. (1989) (234)
The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. (1992) (225)
Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. (1999) (218)
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. (1990) (215)
Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation (2002) (214)
Characterization of the human papillomavirus E2 protein: evidence of trans‐activation and trans‐repression in cervical keratinocytes. (1994) (205)
E3-Ubiquitin Ligase/E6-AP Links Multicopy Maintenance Protein 7 to the Ubiquitination Pathway by a Novel Motif, the L2G Box* (1998) (197)
Retriever is a multiprotein complex for retromer-independent endosomal cargo recycling (2017) (195)
Human papillomaviruses, cervical cancer and cell polarity (2008) (182)
Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A (2005) (170)
Human discs large and scrib are localized at the same regions in colon mucosa and changes in their expression patterns are correlated with loss of tissue architecture during malignant progression (2006) (161)
The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. (1994) (152)
Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300 (2003) (152)
Interaction of viral oncoproteins with cellular target molecules: infection with high‐risk vs low‐risk human papillomaviruses (2010) (149)
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. (1987) (142)
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. (1986) (141)
The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins (2005) (136)
Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes (2003) (134)
HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation (2004) (130)
Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth (1997) (128)
HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation (2001) (128)
Ability of the HPV16 E7 protein to bind RB and induce DNA synthesis is not sufficient for efficient transforming activity in NIH3T3 cells. (1990) (128)
Structures of a Human Papillomavirus (HPV) E6 Polypeptide Bound to MAGUK Proteins: Mechanisms of Targeting Tumor Suppressors by a High-Risk HPV Oncoprotein (2007) (125)
Human Papillomavirus L2 Facilitates Viral Escape from Late Endosomes via Sorting Nexin 17 (2012) (123)
Viruses and the 26S proteasome: hacking into destruction. (2003) (121)
The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. (1995) (121)
Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation. (2017) (115)
Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. (1994) (111)
HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase (2000) (109)
HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. (1996) (99)
HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background (2008) (98)
A Systematic Analysis of Human Papillomavirus (HPV) E6 PDZ Substrates Identifies MAGI-1 as a Major Target of HPV Type 16 (HPV-16) and HPV-18 Whose Loss Accompanies Disruption of Tight Junctions (2010) (98)
The Human Papillomavirus E6 PDZ Binding Motif: From Life Cycle to Malignancy (2015) (97)
Changes in expression of the human homologue of the Drosophila discs large tumour suppressor protein in high-grade premalignant cervical neoplasias. (2002) (96)
Human papillomaviruses and the specificity of PDZ domain targeting (2012) (95)
PDZ domains: the building blocks regulating tumorigenesis. (2011) (94)
HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6 (1999) (91)
Interaction between the HPV-16 E2 transcriptional activator and p53 (1999) (88)
Differential expression of the human homologue of drosophila discs large oncosuppressor in histologic samples from human papillomavirus–associated lesions as a marker for progression to malignancy (2004) (88)
Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. (1997) (87)
Interactions between herpes simplex virus DNA-binding proteins. (1984) (85)
HPV‐16 E2 contributes to induction of HPV‐16 late gene expression by inhibiting early polyadenylation (2012) (81)
Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. (2000) (78)
Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators (2009) (78)
Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. (1993) (78)
Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6 (2000) (77)
The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. (2009) (76)
Comparative Analysis of Transforming Properties of E6 and E7 from Different Beta Human Papillomavirus Types (2011) (75)
The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction (2010) (75)
Repression of p53 transcriptional activity by the HPV E7 proteins. (1997) (75)
HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. (1995) (75)
High-Risk Human Papillomavirus E6 Oncoproteins Interact with 14-3-3ζ in a PDZ Binding Motif-Dependent Manner (2012) (75)
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. (1996) (72)
Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. (1991) (71)
Regulation of Human Papillomavirus Type 16 E7 Activity through Direct Protein Interaction with the E2 Transcriptional Activator (2006) (70)
The role of inflammation in HPV infection of the Oesophagus (2013) (69)
Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. (2002) (69)
The Role of Protein Kinase A Regulation of the E6 PDZ-Binding Domain during the Differentiation-Dependent Life Cycle of Human Papillomavirus Type 18 (2013) (68)
Phosphorylation of the discs large tumour suppressor protein controls its membrane localisation and enhances its susceptibility to HPV E6-induced degradation (2006) (68)
Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines (1999) (67)
Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. (2004) (65)
Crosstalk between the human papillomavirus E2 transcriptional activator and the E6 oncoprotein (2005) (65)
Human tumour viruses and the deregulation of cell polarity in cancer (2012) (65)
Analysis of Multiple HPV E6 PDZ Interactions Defines Type-Specific PDZ Fingerprints That Predict Oncogenic Potential (2016) (60)
Stabilization of HPV16 E6 protein by PDZ proteins, and potential implications for genome maintenance. (2011) (60)
Regulation of the Human Papillomavirus Type 18 E6/E6AP Ubiquitin Ligase Complex by the HECT Domain-Containing Protein EDD (2011) (59)
Skip interacts with the retinoblastoma tumor suppressor and inhibits its transcriptional repression activity. (2002) (58)
Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. (2000) (56)
E6 and E7 from Human Papillomavirus Type 16 Cooperate To Target the PDZ Protein Na/H Exchange Regulatory Factor 1 (2011) (55)
The Human Papillomavirus (HPV) E6* Proteins from High-Risk, Mucosal HPVs Can Direct Degradation of Cellular Proteins in the Absence of Full-Length E6 Protein (2009) (55)
Proteasome-mediated regulation of the hDlg tumour suppressor protein. (2001) (54)
A Novel PDZ Domain Interaction Mediates the Binding between Human Papillomavirus 16 L2 and Sorting Nexin 27 and Modulates Virion Trafficking (2015) (54)
Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations (2013) (53)
The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. (2008) (52)
Regulation of the Discs Large Tumor Suppressor by a Phosphorylation-dependent Interaction with the β-TrCP Ubiquitin Ligase Receptor* (2003) (52)
High-Resolution Characterization of Herpes Simplex Virus Type 1 Transcripts Encoding Alkaline Exonuclease and a 50,000-Dalton Protein Tentatively Identified as a Capsid Protein (1984) (51)
Herpes simplex virus non-structural proteins. IV. Purification of the virus-induced deoxyribonuclease and characterization of the enzyme using monoclonal antibodies. (1983) (51)
The PTPN14 Tumor Suppressor Is a Degradation Target of Human Papillomavirus E7 (2017) (51)
SNX17 Facilitates Infection with Diverse Papillomavirus Types (2012) (50)
Analysis of specificity determinants in the interactions of different HPV E6 proteins with their PDZ domain-containing substrates. (2008) (50)
Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. (2004) (49)
Restoration of MAGI-1 Expression in Human Papillomavirus-Positive Tumor Cells Induces Cell Growth Arrest and Apoptosis (2014) (49)
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. (1994) (48)
Baculovirus expression of the human papillomavirus type 16 capsid proteins: detection of L1-L2 protein complexes. (1991) (48)
Identification of human papillomavirus type 58 lineages and the distribution worldwide. (2011) (47)
E3 ligase EDD1/UBR5 is utilized by the HPV E6 oncogene to destabilize tumor suppressor TIP60 (2016) (47)
The interaction between p53 and papillomaviruses. (1999) (47)
Studies on the herpes simplex virus alkaline nuclease: detection of type-common and type-specific epitopes on the enzyme. (1985) (47)
Conserved Region 3 of Human Papillomavirus 16 E7 Contributes to Deregulation of the Retinoblastoma Tumor Suppressor (2012) (46)
The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity (2001) (45)
Analysis of the PDZ binding specificities of Influenza A Virus NS1 proteins (2011) (44)
Allosteric Activation of Acid α-Glucosidase by the Human Papillomavirus E7 Protein* (2000) (43)
Cancer-Causing Human Papillomavirus E6 Proteins Display Major Differences in the Phospho-Regulation of Their PDZ Interactions (2014) (43)
Interaction of the Human Papillomavirus E6 Oncoprotein with Sorting Nexin 27 Modulates Endocytic Cargo Transport Pathways (2016) (42)
Mutational analysis of the discs large tumour suppressor identifies domains responsible for human papillomavirus type 18 E6-mediated degradation. (2002) (42)
Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and Ej‐ras (1988) (40)
Repair of a minimal DNA double-strand break by NHEJ requires DNA-PKcs and is controlled by the ATM/ATR checkpoint. (2003) (39)
Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. (1987) (39)
Angelman syndrome-associated ubiquitin ligase UBE3A/E6AP mutants interfere with the proteolytic activity of the proteasome (2015) (39)
The Invasive Capacity of HPV Transformed Cells Requires the hDlg-Dependent Enhancement of SGEF/RhoG Activity (2012) (39)
CDK phosphorylation of the discs large tumour suppressor controls its localisation and stability (2009) (39)
Human papillomavirus (HPV)‐18 E6 oncoprotein interferes with the epithelial cell polarity Par3 protein (2014) (38)
The human papillomavirus (HPV) E6 oncoproteins promotes nuclear localization of active caspase 8. (2014) (38)
Modification of Human Papillomavirus Minor Capsid Protein L2 by Sumoylation (2010) (38)
HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures (2004) (37)
Chimaeric HPV E6 proteins allow dissection of the proteolytic pathways regulating different E6 cellular target proteins (2002) (37)
Analysis of human papillomavirus sequences in cell lines recently derived from cervical cancers. (1988) (36)
Comparative transforming potential of different human papillomaviruses associated with non-melanoma skin cancer. (2008) (36)
Ubiquitination and proteasome degradation of the E6 proteins of human papillomavirus types 11 and 18. (2004) (34)
Ski interacts with the evolutionarily conserved SNW domain of Skip. (2001) (34)
Regulation of the hDlg/hScrib/Hugl-1 tumour suppressor complex. (2008) (34)
HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. (1996) (34)
Alternative splicing of human p53 transcripts. (1987) (33)
A Novel Interaction between hScrib and PP1γ Downregulates ERK Signaling and Suppresses Oncogene-Induced Cell Transformation (2013) (33)
Systematic Analysis of the Amino Acid Residues of Human Papillomavirus Type 16 E7 Conserved Region 3 Involved in Dimerization and Transformation (2011) (33)
Human papillomavirus E6 and E7: What remains? (2021) (33)
Cleavage of MAGI-1, a tight junction PDZ protein, by caspases is an important step for cell-cell detachment in apoptosis (2007) (33)
HPV‐18 E6*I modulates HPV‐18 full‐length E6 functions in a cell cycle dependent manner (2004) (32)
Characterization of factors involved in human papillomavirus type 16-mediated immortalization of oral keratinocytes. (1993) (31)
High-resolution characterization of herpes simplex virus type 1 transcripts encoding alkaline exonuclease and a 50,000-dalton protein tentatively identified as a capsid protein (1983) (31)
Interactions between E6AP and E6 proteins from alpha and beta HPV types. (2013) (31)
ZASP Interacts with the Mechanosensing Protein Ankrd2 and p53 in the Signalling Network of Striated Muscle (2014) (31)
Human papillomavirus‐16 E7 protein inhibits the DNA interaction of the TATA binding transcription factor (2002) (30)
Lymphoproliferative response to fusion proteins of human papillomaviruses in patients with cervical intraepithelial neoplasia (1989) (30)
Dissection of the C-Terminal Region of E1A Redefines the Roles of CtBP and Other Cellular Targets in Oncogenic Transformation (2013) (29)
Regulation of human papillomavirus type 16 DNA replication by E2, glucocorticoid hormone and epidermal growth factor. (1997) (29)
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. (2000) (29)
A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth. (2019) (29)
The high-risk HPV E6 oncoprotein preferentially targets phosphorylated nuclear forms of hDlg. (2009) (29)
Mutations in the human papillomavirus type 16 E2 protein identify a region of the protein involved in binding to E1 protein. (1995) (28)
HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers (2013) (28)
Human papillomavirus infection requires the TSG101 component of the ESCRT machinery. (2014) (28)
Adeno-Associated Virus Type 2 Rep Protein Inhibits Human Papillomavirus Type 16 E2 Recruitment of the Transcriptional Coactivator p300 (2000) (27)
HPV-16 E7 functions at the G1 to S phase transition in the cell cycle. (1990) (26)
Mutations in the human papillomavirus type 16 E2 protein identify multiple regions of the protein involved in binding to E1. (1995) (25)
Inhibition of HPV-16 E7 oncogenic activity by HPV-16 E2 (2009) (24)
Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6. (1998) (24)
Expression of the human papillomavirus E7 oncogene during cell transformation is sufficient to induce susceptibility to lysis by activated macrophages. (1991) (24)
Human papillomavirus infection, cancer & therapy. (2009) (24)
Upsetting the Balance: When Viruses Manipulate Cell Polarity Control (2018) (24)
Disordered interactome of human papillomavirus. (2014) (23)
Lack of immortalizing activity of a human papillomavirus type 16 variant DNA with a mutation in the E2 gene isolated from normal human cervical keratinocytes. (1992) (23)
The HPV-18 E7 CKII phospho acceptor site is required for maintaining the transformed phenotype of cervical tumour-derived cells (2019) (23)
Mechano-Dependent Phosphorylation of the PDZ-Binding Motif of CD97/ADGRE5 Modulates Cellular Detachment. (2018) (23)
The Mdm2 Ubiquitin Ligase Enhances Transcriptional Activity of Human Papillomavirus E2 (2008) (23)
Regulation of the DLG tumor suppressor by β‐catenin (2012) (23)
Human Papillomavirus Infectious Entry and Trafficking Is a Rapid Process (2015) (23)
The Human Papillomavirus E6 PDZ Binding Motif Links DNA Damage Response Signaling to E6 Inhibition of p53 Transcriptional Activity (2018) (23)
The high-risk HPV E6 target scribble (hScrib) is required for HPV E6 expression in cervical tumour-derived cell lines (2016) (22)
In Vivo Functional Selection Identifies Cardiotrophin-1 as a Cardiac Engraftment Factor for Mesenchymal Stromal Cells (2017) (22)
hDLG/SAP97, a member of the MAGUK protein family, is a novel caspase target during cell-cell detachment in apoptosis (2005) (22)
Differential Regulation of Cell-Cell Contact, Invasion and Anoikis by hScrib and hDlg in Keratinocytes (2012) (22)
HPV Oncoproteins and the Ubiquitin Proteasome System: A Signature of Malignancy? (2020) (22)
Papillomaviruses and Endocytic Trafficking (2018) (21)
The expression of human papillomavirus type 18 E6 protein in bacteria and the production of anti-E6 antibodies. (1986) (20)
A naturally occurring variant of HPV-16 E7 exerts increased transforming activity through acquisition of an additional phospho-acceptor site. (2017) (20)
Redistribution of the discs large tumor suppressor protein during mitosis. (2003) (20)
Regulation of translational efficiency by different splice variants of the Disc large 1 oncosuppressor 5′‐UTR (2011) (19)
Targeting the Retinoblastoma Protein by MC007L, Gene Product of the Molluscum Contagiosum Virus: Detection of a Novel Virus-Cell Interaction by a Member of the Poxviruses (2008) (19)
p53 polymorphism and risk of cervical cancer (1998) (19)
A functional interaction between the MAGUK protein hDlg and the gap junction protein connexin 43 in cervical tumour cells. (2012) (19)
The VPS4 component of the ESCRT machinery plays an essential role in HPV infectious entry and capsid disassembly (2017) (19)
Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. (2002) (19)
MAGUKs, scaffolding proteins at cell junctions, are substrates of different proteases during apoptosis (2011) (18)
PDZRN3/LNX3 Is a Novel Target of Human Papillomavirus Type 16 (HPV-16) and HPV-18 E6 (2014) (18)
The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis (2021) (18)
Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ-ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. (1995) (17)
Cloning and functional analysis of the promoter region of the human Disc large gene. (2008) (16)
Transformation assays for HPV oncoproteins. (2005) (16)
Production of antibodies of predetermined specificity against herpes simplex virus DNA polymerase and their use in characterization of the enzyme (1988) (16)
Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells (2011) (16)
Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses (2008) (16)
Transformation of primary BRK cells by human papillomavirus type 16 and EJ-ras is increased by overexpression of the viral E2 protein. (1990) (16)
The Human Papillomavirus E7 Proteins Associate with p190RhoGAP and Alter Its Function (2014) (15)
Human Papillomavirus 16 Infection Induces VAP-Dependent Endosomal Tubulation (2018) (14)
A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor (2016) (14)
The mechanisms and implications of hScrib regulation of ERK (2010) (13)
SGEF forms a complex with Scribble and Dlg1 and regulates epithelial junctions and contractility (2019) (13)
Exome sequencing of a colorectal cancer family reveals shared mutation pattern and predisposition circuitry along tumor pathways (2015) (13)
The function of the human papillomavirus oncogenes (2001) (12)
Monitoring HPV-16 E7 phosphorylation events. (2017) (12)
Mitotic control of human papillomavirus genome-containing cells is regulated by the function of the PDZ-binding motif of the E6 oncoprotein (2017) (12)
Analysis of human papillomavirus type 16 polypeptides in transformed primary cells. (1988) (12)
Interaction of HPV E6 oncoproteins with specific proteasomal subunits. (2013) (12)
PDZ Domain-Containing Protein NHERF-2 Is a Novel Target of Human Papillomavirus 16 (HPV-16) and HPV-18 (2019) (11)
Regulation of the human papillomavirus oncoproteins by differential phosphorylation (2004) (11)
Cellular localization of MAGI-1 caspase cleavage products and their role in apoptosis (2007) (11)
Human papillomavirus oncoproteins and post-translational modifications: generating multifunctional hubs for overriding cellular homeostasis (2019) (11)
HPV-16 virions can remain infectious for 2 weeks on senescent cells but require cell cycle re-activation to allow virus entry (2018) (9)
Characterizing the spatio-temporal role of sorting nexin 17 in human papillomavirus trafficking. (2017) (9)
Identification of E6AP-independent degradation targets of HPV E6. (2019) (9)
Human Papillomavirus 58 E7 T20I/G63S Variant Isolated from an East Asian Population Possesses High Oncogenicity (2020) (9)
Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity (2017) (9)
Monoclonal antibodies to herpes simplex virus thymidine kinase. (1984) (8)
Human papillomavirus type 16 E 7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E 7 transforming activity (1997) (8)
Human Papillomavirus 16 L2 Recruits both Retromer and Retriever Complexes during Retrograde Trafficking of the Viral Genome to the Cell Nucleus (2020) (8)
Human Papillomavirus Infection Requires the CCT Chaperonin Complex (2021) (8)
Acquisition of a phospho-acceptor site enhances HPV E6 PDZ-binding motif functional promiscuity. (2020) (7)
In vitro assays of substrate degradation induced by high-risk HPV E6 oncoproteins. (2005) (7)
Hpv Proteins as Targets for Therapeutic Intervention (2004) (7)
Phosphorylation of Human Papillomavirus Type 16 L2 Contributes to Efficient Virus Infectious Entry (2019) (6)
Oncogenicitiy Comparison of Human Papillomavirus Type 52 E6 Variants. (2019) (6)
Oncogenic comparison of human papillomavirus type 58 E7 variants (2018) (6)
High-Resolution Characterization ofHerpesSimplex Virus Type1Transcripts Encoding Alkaline Exonuclease anda 50,000-Dalton Protein Tentatively Identified asaCapsid Protein (1983) (6)
Human papillomavirus E6 protein interactions (2002) (6)
Characterization of Novel Transcripts of Human Papillomavirus Type 16 Using Cap Analysis Gene Expression Technology (2014) (6)
Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples (2022) (6)
Loss of the E6AP Ubiquitin Ligase Induces p53-Dependent Phosphorylation of Human Papillomavirus 18 E6 in Cells Derived from Cervical Cancer (2022) (5)
The Mdm 2 Ubiquitin Ligase Enhances Transcriptional Activity of Human Papillomavirus E 2 (2008) (5)
Loss of HPV-16 E7 dependence in cells transformed by HPV-16 E7 plus EJ-ras correlates with increased c-myc expression. (1991) (5)
Spotlight on COVID‐19: from biology to therapy and prevention (2020) (5)
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy (2015) (5)
Amplification and Overexpression of c‐myc Proto‐Oncogene Correlate With the Loss of Glucocorticoid Dependence in Rodent Cells Transformed by Human Papillomavirus Type 16 (1989) (4)
Regulation of the human papillomavirus oncoproteins by differential phosphorylation. (2001) (4)
The Dimeric Form of HPV16 E6 Is Crucial to Drive YAP/TAZ Upregulation through the Targeting of hScrib (2021) (4)
Virology under the Microscope—a Call for Rational Discourse (2023) (4)
The biology of papillomavirus PDZ associations: what do they offer papillomaviruses? (2021) (3)
Diverse Papillomavirus Types Induce Endosomal Tubulation (2019) (3)
Increased Growth of a Newly Established Mouse Epithelial Cell Line Transformed with HPV-16 E7 in Diabetic Mice (2016) (3)
Choosing the right path: membrane trafficking and infectious entry of small DNA tumor viruses. (2019) (3)
Spotlight on COVID‐19: eighteen months on (2021) (2)
Human DLG1 and SCRIB Are Distinctly Regulated Independently of HPV-16 during the Progression of Oropharyngeal Squamous Cell Carcinomas: A Preliminary Analysis (2021) (2)
A Single Maturation Cleavage Site in Adenovirus Impacts Cell Entry and Capsid Assembly (2016) (2)
Regulation of HPV E7 Stability by E6-Associated Protein (E6AP) (2022) (2)
High risk HPV E6 oncoproteins impair the subcellular distribution of the four and a half LIM-only protein 2 (FHL2). (2015) (2)
A genetic polymorphism determines susceptibility to human papillomavirus associated cancers (1998) (2)
Characterisation of cellular changes which influence progression of human papillomavirus type-16 immortalised keratinocytes to anchorage-independent phenotype. (1996) (1)
Words of Advice: How to be a good Principal Investigator (2021) (1)
Complementation of a p 300 / CBP defective-binding mutant of adenovirus E 1 a by human papillomavirus E 6 proteins (1)
Virology under the Microscope—a Call for Rational Discourse (2023) (1)
Human Papillomavirus: Targets for Therapeutic Intervention (2002) (1)
response tofusion proteins ofhuman papillomaviruses inpatients withcervical intraepithelial neoplasia (1989) (1)
Virology under the Microscope—a Call for Rational Discourse (2023) (1)
The role of inflammation in HPV infection of the Oesophagus (2013) (1)
Viral oncoproteins and ubiquitination: accessing a cellular toolbox for modifying protein function (2017) (1)
Inhibition of kinase IKKβ suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6 (2021) (1)
CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells (2022) (1)
Detection of HPV-16 E2 Protein in Cervical Keratinocytes (1994) (1)
Retriever , a multiprotein complex for retromer-independent 1 endosomal cargo recycling 2 (2017) (0)
HPV-18E6 Inhibits Interactions between TANC2 and SNX27 in a PBM-Dependent Manner and Promotes Increased Cell Proliferation (2022) (0)
PDZ Domain-Containing Protein NHERF-2 is a Novel Target of Human 1 Papillomavirus type 16 ( HPV-16 ) and HPV-18 2 (2020) (0)
A new approach for screening cervical cancer by characterization of transcripts using CAGE technology. (2015) (0)
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy (2015) (0)
entwickelen to screening methods for identifying individuals at risk of disease associated with different polymorphic forms of wild-type p53 associated, (1998) (0)
Correction: Clinical validation of full HR-HPV genotyping HPV Selfy assay according to the international guidelines for HPV test requirements for cervical cancer screening on clinician-collected and self-collected samples (2022) (0)
HPV-16 E7 Interacts with the Endocytic Machinery via the AP2 Adaptor μ2 Subunit (2022) (0)
X-ray crystal structure of MAGI-1 PDZ1 bound to the C-terminal peptide of HPV18 E6 (2007) (0)
LadyMed™ Test for Human Papillomavirus Genotyping Directly from Self-Collected Vaginal Samples Without Any DNA Extraction Step: A Clinical Trial on Cervical Cancer Screening Population (2020) (0)
Phospho-regulation of high-risk HPV E6 PDZ/14-3-3 interactions (2014) (0)
Molecular dissection of the E6 PBM identifies essential residues regulating Chk1 phosphorylation and subsequent 14-3-3 recognition (2023) (0)
Highlights in Virology: Viral miRNAs and Flaviviruses (2019) (0)
Coactivator p 300 Recruitment of the Transcriptional Inhibits Human Papillomavirus Type 16 E 2 Adeno-Associated Virus Type 2 Rep Protein (2000) (0)
TransformationTargets in Oncogenic Redefines the Roles of CtBP and Other Dissection of the C-Terminal Region of E1A (2014) (0)
Biochemical Differences Among Naturally Occurring HPV-16 E6 Variants (2019) (0)
Identiﬁcation of Human Papillomavirus Type 58 Lineages and the Distribution Worldwide Variant Lineage (2011) (0)
DLG1 (discs, large homolog 1 (Drosophila)) (2011) (0)
Inhibition of kinase IKKβ suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6 (2021) (0)
MAML1‐induced HPV E6 oncoprotein stability is required for cellular proliferation and migration of cervical tumor‐derived cells (2023) (0)
Cordano, P. and Gillan, V. and Bratlie, S. and Bouvard, V. and Banks, L (2008) (0)
The mechanisms behind human papillomavirus-associated cancer: the role of PDZ recognition in malignant progression (2011) (0)
HPV-16 virions can remain infectious for 2 weeks on senescent cells but require cell cycle re-activation to allow virus entry (2018) (0)
Novel effect of the high risk-HPV E7 CKII phospho-acceptor site on polarity protein expression (2022) (0)
Papillomavirus Types SNX17 Facilitates Infection with Diverse (2014) (0)
Analysis of hDLG phosphorylation during the cell cycle (2001) (0)
University of Birmingham The role of protein kinase A regulation of the E 6 PDZ-binding domain during the differentiation-dependent life cycle of human papillomavirus type 18 (2013) (0)
Oncogenic Potential of Naturally Occurring HPV- 16 E6 Variants (2019) (0)
Repression of Memo1, a Novel Target of Human Papillomavirus Type 16 E7, Increases Cell Proliferation in Cervical Cancer Cells (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence Banks?

Lawrence Banks is affiliated with the following schools:

Lawrence Banks's Academic­Influence.com Rankings

Lawrence Banks's Degrees

Similar Degrees You Can Earn

Why Is Lawrence Banks Influential?

Lawrence Banks's Published Works

Published Works

What Schools Are Affiliated With Lawrence Banks?

Lawrence Banks's AcademicInfluence.com Rankings